aceclidine hydrochloride · Lenz Therap · NDA 218585
Vizz
Earliest generic entry, as listed
15 Mar 2044
Blocked by patent: US 12414942. Only method-of-use patents remain, so a generic may carve out the protected indication and enter earlier.
Listed patents · 7 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 12414942 | use U-3741 | 15 Mar 2044 |
| US 12128036 | use U-3741 | 8 Oct 2039 |
| US 12533347 | use U-3741 | 8 Oct 2039 |
| US 12653779 | use U-3741 | 18 Jun 2035 |
| US 10052313 | product, use U-3741 | 24 Mar 2034 |
| US 11179328 | use U-3741 | 24 Mar 2034 |
| US 9844537 | product, use U-3741 | 24 Mar 2034 |
Exclusivities · 1 unexpired
| NCE | new chemical entity (5 years) | 31 Jul 2030 |
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 218585 · 001 · RLD | solution/drops, ophthalmic | EQ 1.44% BASE | 15 Mar 2044 |